2013
DOI: 10.1536/ihj.54.149
|View full text |Cite
|
Sign up to set email alerts
|

Neutrophil Elastase Inhibitor Sivelestat Attenuates Perioperative Inflammatory Response in Pediatric Heart Surgery With Cardiopulmonary Bypass

Abstract: SummaryCardiopulmonary bypass (CPB) evokes activation of a systemic inflammatory response. Sivelestat has been used clinically to treat acute lung injury associated with systemic inflammatory response syndrome. This prospective, doubleblind, randomized study was designed to evaluate the effects of sivelestat in the perioperative period of elective pediatric open-heart surgery with CPB. Twenty-six consecutive pediatric patients weighing between 5 and 10 kg and undergoing open-heart surgery with CPB were divided… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
19
0
1

Year Published

2014
2014
2022
2022

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 22 publications
(21 citation statements)
references
References 23 publications
1
19
0
1
Order By: Relevance
“…sivelestat) inhibitors of NE . The use of sivelestat, in particular, confirmed the potential of targeting NE for the treatment of disorders such as acute lung injury , complications arising from myocardial surgery , organ transplantation and several model of I/R injury . However, at present the specific role(s) of NE in I/R injury remains poorly understood.…”
Section: Discussionmentioning
confidence: 91%
“…sivelestat) inhibitors of NE . The use of sivelestat, in particular, confirmed the potential of targeting NE for the treatment of disorders such as acute lung injury , complications arising from myocardial surgery , organ transplantation and several model of I/R injury . However, at present the specific role(s) of NE in I/R injury remains poorly understood.…”
Section: Discussionmentioning
confidence: 91%
“…Interventions which may prove efficacious in the adult brain can not necessarily be extrapolated to function similarly or safely in the developing brain (Natale et al, 2006). Of note, inhibition of human NE using the compound sivelestat (ONO 5046, Ono Pharmaceuticals Co., Ltd.) has demonstrated safety in a pediatric population for acute respiratory distress syndrome (Kikuchi et al, 2006; Matsumoto et al, 2009), as well as efficacy attenuating the post-operative inflammatory response and improving clinical outcomes after cardiopulmonary surgery in children (Inoue et al, 2013; Kohira et al, 2013). Although acute NE inhibition failed to improve long-term outcomes in the current study, these clinical findings suggest that administration of optimized NE inhibitors to pediatric patients may be a safe and feasible option after pediatric TBI.…”
Section: Discussionmentioning
confidence: 99%
“…In patients with ARDS secondary to sepsis, selective neutrophil elastase inhibitor sivelestat has been reported to improve oxygenation, reduce lung injury and shorten the length of ICT stay 160-161 . In the context of postoperative ALI without sepsis, while it improves inflammatory mediator levels, the benefit on prognosis is unclear 162-164 .…”
Section: Conclusion and Way Forwardmentioning
confidence: 99%